Xagenic
Empowering clinicians with rapid, near-patient molecular testing for improved patient care and reduced healthcare costs.
Empowering clinicians with rapid, near-patient molecular testing for improved patient care and reduced healthcare costs.
Xagenic, based in Toronto, Canada, is a trailblazer in molecular diagnostics, dedicated to developing cutting-edge technology for rapid, near-patient diagnostic testing. Their mission is to equip clinicians with the ability to make timely treatment decisions during the initial patient consultation, ultimately enhancing patient care and reducing healthcare expenses. Xagenic’s innovative approach enables swift, enzyme-free detection of nucleic acids from clinical samples. The company has introduced a user-friendly, fully automated technology platform tailored for widespread diagnostic testing outside traditional clinical laboratories. Their focus is on the development of infectious disease tests capable of rapidly identifying various analytes, providing clinically actionable results in scenarios where fast test turnaround is critical. Founded in 2010, Xagenic operates within the biotechnology, healthcare, and medical devices sectors. Notably, the company received a $15.00M Series B investment on 09 July 2015 from Domain Associates, CTI Life Sciences Fund, The Ontario Capital Growth, and BDC Healthcare Venture, signifying recognized support from reputable investors in the industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $15.00M | 4 |
|
09 Jul 2015 |
| Series B | $25.50M | 3 |
|
14 Jul 2014 |
| Venture Round | $9.59M | - | 10 Dec 2013 | |
| Grant | $990.00K | 1 |
|
19 Feb 2013 |
| Series A | $10.00M | 4 |
|
30 Jan 2012 |
No recent news or press coverage available for Xagenic.
We care about your data, and we'd love to use cookies make your experience better.